Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 PublicationRecord Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11ReportContainer
.... 15.45 M11ReportSection01
.... 15.46 M11ReportSection02
.... 15.47 M11ReportSection03
.... 15.48 M11ReportSection04
.... 15.49 M11ReportSection05
.... 15.50 M11ReportSection06
.... 15.51 M11ReportSection07
.... 15.52 M11ReportSection08
.... 15.53 M11ReportSection09
.... 15.54 M11ReportSection10
.... 15.55 M11ReportSection11
.... 15.56 M11ReportSection12
.... 15.57 M11ReportSection13
.... 15.58 M11ReportSection14
.... 15.59 MetaanalysisEligibilityCriteria
.... 15.60 MetaanalysisOutcomeDefinition
.... 15.61 MetaanalysisStudyGroup
.... 15.62 NetEffectContribution
.... 15.63 NetEffectContributionList
.... 15.64 NetEffectContributions
.... 15.65 NetEffectEstimate
.... 15.66 NonComparativeEvidence
.... 15.67 OutcomeDefinition
.... 15.68 OutcomeImportance
.... 15.69 OutcomeList
.... 15.70 OutcomeMeasureReport
.... 15.71 OutcomeVariablesList
.... 15.72 ParticipantFlowEvidence
.... 15.73 ParticipantFlowEvidenceVariable
.... 15.74 ParticipantFlowReasonEvidenceVariable
.... 15.75 ParticipantFlowReport
.... 15.76 ParticipantFlowVariablesList
.... 15.77 PICOSpecification
.... 15.78 PICOTaggedComposition
.... 15.79 PICOTaggedEvidence
.... 15.80 PreprintCitation
.... 15.81 Rating
.... 15.82 Recommendation
.... 15.83 RecommendationAction
.... 15.84 RecommendationEligibilityCriteria
.... 15.85 RecommendationJustification
.... 15.86 RecommendationPlan
.... 15.87 RecommendationRating
.... 15.88 ResearchStudyDataDictionary
.... 15.89 ResearchStudySite
.... 15.90 ResearchStudySupport
.... 15.91 RiskOfBias
.... 15.92 SearchResults
.... 15.93 SearchStrategy
.... 15.94 SingleStudyEvidence
.... 15.95 SoaPlanDefinition
.... 15.96 SoftwareCitation
.... 15.97 StatisticModel
.... 15.98 StudyComponent
.... 15.99 StudyDesign
.... 15.100 StudyEligibilityCriteria
.... 15.101 StudyGroup
.... 15.102 StudyRegistryRecord
.... 15.103 SummaryOfFindings
.... 15.104 SummaryOfNetEffect
.... 15.105 SystematicReview
.... 15.106 SystematicReviewEligibilityCriteria
.... 15.107 SystematicReviewExcludedStudies
.... 15.108 SystematicReviewIncludedStudies
.... 15.109 VariableDefinition
.... 15.110 WebPageCitation
.... 15.111 ArtifactAssessmentCompared
.... 15.112 ArtifactAssessmentDateAsRating
.... 15.113 ArtifactPublicationStatus
.... 15.114 ArtifactRecorder
.... 15.115 CharacteristicTiming
.... 15.116 CiteAs
.... 15.117 EvidenceVariableHandlingDetail
.... 15.118 GuidelineRegistration
.... 15.119 NumberAnalyzed
.... 15.120 RelatesToClassifier
.... 15.121 RelatesToWithQuotation
.... 15.122 RelativeOutcomeImportance
.... 15.123 RelevantForAutomatedMatching
.... 15.124 ResearchStudyExcludedStudy
.... 15.125 ResearchStudyIncludedStudy
.... 15.126 ResearchStudyIsLowInterventionTrial
.... 15.127 ResearchStudyIsRareDisease
.... 15.128 ResearchStudyNumberOfStudiesIdentified
.... 15.129 ResearchStudyNumberOfStudiesIncluded
.... 15.130 ResearchStudySaeReportingMethod
.... 15.131 ResearchStudySearchStrategy
.... 15.132 ResearchStudySponsorConfidentialityStatement
.... 15.133 ResearchStudyStudyAmendment
.... 15.134 ResearchStudySystematicReviewEligibilityCriteria
.... 15.135 StatisticModelExpression
.... 15.136 StatisticModelIncludeIf
.... 15.137 Desirability Codes Value Set
.... 15.138 EBMonFHIR Profile Name Value Set
.... 15.139 Evidence Rating System Classifier Codes Value Set
.... 15.140 PICO Classification Value Set
.... 15.141 Recommendation Justification Classifier Codes Value Set
.... 15.142 Research Study Document Types Value Set
.... 15.143 ResearchStudy Classifier Value Set
.... 15.144 Search Strategy Characteristic Value Set
.... 15.145 Desirability Code System
.... 15.146 EBMonFHIR Profile Name Code System
.... 15.147 Evidence Rating System Classifier Code System
.... 15.148 Research Study Document Types Code System
.... 15.149 Search Strategy Characteristic Code System
.... 15.150 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.151 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.152 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.153 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.154 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.155 179899
.... 15.156 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.157 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.158 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.159 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.160 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.161 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.162 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.163 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.164 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.165 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.166 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.167 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.168 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.169 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.170 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.171 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.172 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.173 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.174 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.175 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.176 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.177 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.178 27979893 6. Glycemic Targets.
.... 15.179 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.180 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.181 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.182 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.183 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.184 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.185 30467172 Finding my inner Wonder Woman.
.... 15.186 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.187 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
.... 15.188 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.189 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.190 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.191 367832
.... 15.192 367833
.... 15.193 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.194 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.195 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.196 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.197 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.198 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.199 Add-on Amlodipine at 6 weeks
.... 15.200 Adults with diabetes mellitus type 2
.... 15.201 Adults with type 2 diabetes and CVD and CKD
.... 15.202 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.203 Adverse event free and hypertension control
.... 15.204 Adverse event free and hypertension control at 12 weeks
.... 15.205 Adverse Events Report for NCT03421379
.... 15.206 Adverse Events Report for NCT03640312
.... 15.207 Age
.... 15.208 Age with comparator
.... 15.209 Age with intervention
.... 15.210 Aircraft Type
.... 15.211 Aircraft Type with comparator
.... 15.212 Aircraft Type with intervention
.... 15.213 Altitude
.... 15.214 Altitude comparing intervention vs. comparator
.... 15.215 Altitude for enrolled group
.... 15.216 Altitude for screened group
.... 15.217 Altitude with comparator
.... 15.218 Altitude with intervention
.... 15.219 Analysis of formalin-fixed paraffin-embedded and blood and blood samples (NCT05327010)
.... 15.220 Analyzed Group in PARACHUTE Trial
.... 15.221 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.222 Anticoagulation for COVID-19 Combined RCTs PrePrint
.... 15.223 Assess emergent resistant mutations (NCT05327010)
.... 15.224 Baseline Characteristics Report for NCT03421379
.... 15.225 Baseline Characteristics Report for NCT03640312
.... 15.226 Baseline Characteristics Report for QUARTET Trial
.... 15.227 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.228 Baseline Measures List for PARACHUTE Trial
.... 15.229 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.230 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.231 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.232 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.233 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.234 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.235 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.236 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.237 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.238 BP-CONTROL Cardiovascular Outcomes Component: intensive versus standard blood-pressure control in adults at increased cardiovascular risk
.... 15.239 BP-CONTROL Master Protocol: blood-pressure targets in adults at increased cardiovascular risk
.... 15.240 Candesartan 8 mg once daily
.... 15.241 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.242 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.243 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.244 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.245 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.246 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.247 Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)
.... 15.248 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.249 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.250 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.251 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.252 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.253 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.254 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.255 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.256 Citation for EBMonFHIR Implementation Guide
.... 15.257 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.258 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.259 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.260 Clinical benefit rate (CBR) (NCT05327010)
.... 15.261 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.262 Comparative Evidence Report Expanded for QUARTET USA Trial
.... 15.263 Comparative Evidence Report for QUARTET USA Trial
.... 15.264 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.265 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.266 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.267 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.268 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.269 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.270 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.271 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.272 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.273 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.274 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.275 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.276 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.277 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.278 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.279 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.280 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.281 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.282 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.283 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.284 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.285 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.286 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.287 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.288 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.289 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.290 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.291 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.292 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.293 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.294 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.295 ComparatorDefinition: Standard care
.... 15.296 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.297 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.298 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.299 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.300 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.301 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.302 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.303 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.304 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.305 Computable_Publishing_LLC
.... 15.306 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.307 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.308 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.309 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.310 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.311 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.312 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.313 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.314 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.315 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.316 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.317 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.318 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.319 ConceptualCohortDefinition: Nonfatal stroke
.... 15.320 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.321 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.322 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.323 ConceptualCohortDefinition: Severe obesity
.... 15.324 ConceptualCohortDefinition: T1DM or T2DM
.... 15.325 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.326 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.327 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.328 ConceptualCohortDefinition_Cardiovascular_event
.... 15.329 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.330 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.331 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.332 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.333 Correlate baseline mutations with treatment response (NCT05327010)
.... 15.334 Correlate changes in ctDNA variant allele frequencies with response (NCT05327010)
.... 15.335 Correlate mutation profiles with tumor sequencing (NCT05327010)
.... 15.336 Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response (NCT05327010)
.... 15.337 COVID_19PneumoniaHospitalizedAdult
.... 15.338 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.339 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.340 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.341 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.342 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.343 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.344 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.345 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.346 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.347 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.348 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.349 CTIS2025-523977-40-00 Eligibility Criteria - ARMYDA Study on Coronary Plaque Change with Semaglutide in Diabetes with ACS
.... 15.350 DatabaseCitation: Citation for FEvIR Platform
.... 15.351 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.352 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.353 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.354 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.355 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.356 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.357 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.358 declined randomization in PARACHUTE Study
.... 15.359 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.360 Delany-Moretlwe 2022 clinical trial
.... 15.361 Diabetes treatment medication
.... 15.362 Diastolic blood pressure at 12 weeks
.... 15.363 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.364 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.365 DichotomousIntendedOutcome: New onset depression
.... 15.366 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.367 DichotomousIntendedOutcome: Remission of diabetes
.... 15.368 DichotomousIntendedOutcome: Treatment with opioids
.... 15.369 DIO: Mortality
.... 15.370 Duration of response (NCT05327010)
.... 15.371 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.372 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.373 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.374 Eligibility criteria for NMA_Diabetes
.... 15.375 Eligibility Criteria for QUARTET USA Trial
.... 15.376 Enrolled Group for QUARTET USA Trial
.... 15.377 Enrolled Group PARACHUTE Trial
.... 15.378 Ethnic Group
.... 15.379 Ethnic Group with comparator
.... 15.380 Ethnic Group with intervention
.... 15.381 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.382 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.383 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.384 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.385 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.386 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.387 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.388 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.389 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.390 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.391 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.392 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.393 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.394 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.395 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.396 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.397 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.398 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.399 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.400 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.401 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.402 EvidenceReportSectionCode Value Set
.... 15.403 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.404 EvidenceVariable Handling Extension Value Set
.... 15.405 EvidenceVariable: case_id
.... 15.406 EvidenceVariable: Patient id
.... 15.407 EvidenceVariable: Time of measurement
.... 15.408 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.409 Example of a ResearchStudySite
.... 15.410 Example of statistical model expression
.... 15.411 Excluded from PARACHUTE Study
.... 15.412 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.413 ExposureVariable: Age (as continuous variable)
.... 15.414 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.415 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.416 ExposureVariable: pht013093.v1.p1 RACE
.... 15.417 ExposureVariable: pht013093.v1.p1 SEX
.... 15.418 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.419 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.420 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.421 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.422 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.423 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.424 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.425 Family History of Parachute Use
.... 15.426 Family History of Parachute Use with comparator
.... 15.427 Family History of Parachute Use with intervention
.... 15.428 Frequent Flier
.... 15.429 Frequent Flier with comparator
.... 15.430 Frequent Flier with intervention
.... 15.431 Gene expression profiling (NCT05327010)
.... 15.432 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.433 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.434 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.435 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.436 Glucagon Nasal Powder (Experimental)
.... 15.437 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.438 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.439 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.440 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.441 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.442 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.443 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.444 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.445 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.446 GroupAssignment: Quadpill vs. Candesartan
.... 15.447 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.448 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.449 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.450 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.451 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.452 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.453 Health Survey Score Total
.... 15.454 Health Survey Score Total comparing intervention vs. comparator
.... 15.455 Health Survey Score Total with comparator
.... 15.456 Health Survey Score Total with intervention
.... 15.457 Health Survey Score-Mental Health Subscore
.... 15.458 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.459 Health Survey Score-Mental Health Subscore with comparator
.... 15.460 Health Survey Score-Mental Health Subscore with intervention
.... 15.461 Health Survey Score-Physical Health Subscore
.... 15.462 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.463 Health Survey Score-Physical Health Subscore with comparator
.... 15.464 Health Survey Score-Physical Health Subscore with intervention
.... 15.465 Health-related Quality of Life (Mental) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.466 Health-related Quality of Life (NCT03640312)
.... 15.467 Health-related Quality of Life (Physical) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.468 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.469 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.470 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.471 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.472 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.473 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.474 Height
.... 15.475 Height with comparator
.... 15.476 Height with intervention
.... 15.477 High Blood Pressure Medication Value Set
.... 15.478 History of Acrophobia
.... 15.479 History of Acrophobia with comparator
.... 15.480 History of Acrophobia with intervention
.... 15.481 History of Broken Bones
.... 15.482 History of Broken Bones with comparator
.... 15.483 History of Broken Bones with intervention
.... 15.484 History of Parachute Use
.... 15.485 History of Parachute Use with comparator
.... 15.486 History of Parachute Use with intervention
.... 15.487 Hypertension Control at 12 weeks
.... 15.488 ICD-10-GM Terminale Codes
.... 15.489 Incidence of adverse events (NCT05327010)
.... 15.490 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.491 Injury Severity Score 30 days after Impact with comparator
.... 15.492 Injury Severity Score 30 days after Impact with intervention
.... 15.493 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.494 Injury Severity Score on Impact with comparator
.... 15.495 Injury Severity Score on Impact with intervention
.... 15.496 International vs Domestic Flight
.... 15.497 International vs Domestic Flight with comparator
.... 15.498 International vs Domestic Flight with intervention
.... 15.499 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.500 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.501 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.502 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.503 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.504 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.505 Investigator
.... 15.506 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.507 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.508 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.509 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.510 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.511 Jumping from aircraft with empty backpack
.... 15.512 Jumping from aircraft with parachute
.... 15.513 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.514 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.515 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.516 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.517 M11 Report for M11ResearchStudy Template
.... 15.518 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.519 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.520 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.521 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.522 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.523 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.524 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.525 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.526 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.527 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.528 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.529 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.530 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.531 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.532 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.533 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.534 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.535 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.536 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.537 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.538 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.539 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.540 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.541 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.542 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.543 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.544 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.545 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.546 M11ResearchStudy Template
.... 15.547 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.548 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.549 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.552 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.553 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.554 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.555 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.556 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.557 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.558 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.559 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.560 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.561 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.562 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.563 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.564 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.565 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.566 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.567 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.568 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.569 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.570 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.571 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.572 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.573 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.574 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.575 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.576 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.577 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.578 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.579 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.580 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.581 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.582 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.583 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.584 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.585 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.586 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.587 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.588 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.589 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.590 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.591 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.592 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.593 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.594 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.595 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.596 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.597 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.598 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.599 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.600 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.601 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.602 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.603 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.604 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.605 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.606 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.607 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.608 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.609 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.610 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.611 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.612 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.613 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes
.... 15.614 Major adverse cardiovascular events (composite endpoint)
.... 15.615 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.616 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.617 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.618 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.619 Mean Change in Serum Creatinine (NCT03640312)
.... 15.620 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.621 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.622 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.623 Mean Change in Serum Potassium (NCT03640312)
.... 15.624 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.625 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.626 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.627 Mean Change in Serum Sodium (NCT03640312)
.... 15.628 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.629 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.630 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.631 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.632 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.633 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.634 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.635 Mean Systolic Blood Pressure (NCT03640312)
.... 15.636 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.637 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.638 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.639 Median Age of Parachute Intervention Group
.... 15.640 Medication Adherence (NCT03640312)
.... 15.641 Medication Adherence at 12 weeks
.... 15.642 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.643 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.644 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.645 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.646 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.647 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.648 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.649 Mortality at 14 days
.... 15.650 NCT03421379 Eligibility Criteria
.... 15.651 NCT03640312 Eligibility Criteria
.... 15.652 NCT04401202 Eligibility Criteria
.... 15.653 NCT04401202_Enrollment_Group
.... 15.654 NCT05327010 Eligibility Criteria
.... 15.655 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.656 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.657 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.658 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.659 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.660 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.661 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.662 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.663 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.664 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.665 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.666 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.667 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.668 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.669 NHANES SEQN Respondent Sequence Number
.... 15.670 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.671 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.672 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.673 NT-proBNP Study Data Dictionary
.... 15.674 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.675 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.676 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.677 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.678 Objective response rate (ORR) (NCT05327010)
.... 15.679 Organ support-free days
.... 15.680 Outcome Importance Rating 100 of All-cause mortality
.... 15.681 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.682 Outcome Importance Rating 5 of New onset depression
.... 15.683 Outcome Importance Rating 5 of Remission of diabetes
.... 15.684 Outcome Importance Rating 5 of Treatment with opioids
.... 15.685 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.686 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.687 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.688 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.689 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.690 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.691 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.692 Outcome Measure List for QUARTET USA Trial
.... 15.693 Outcome Measure Report for QUARTET USA Trial
.... 15.694 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.695 Outcome Measures Report for NCT03421379
.... 15.696 Outcome Measures Report for NCT03640312
.... 15.697 Outcome Variables List for PARACHUTE Trial
.... 15.698 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.699 Outcome: Death or Major Traumatic Injury on Impact
.... 15.700 Outcome: Injury Severity Score 30 days after Impact
.... 15.701 Outcome: Injury Severity Score on Impact
.... 15.702 OutcomeDefinition for All-cause mortality
.... 15.703 OutcomeDefinition for Body weight
.... 15.704 OutcomeDefinition for Cardiovascular mortality
.... 15.705 OutcomeDefinition for End-stage kidney disease
.... 15.706 OutcomeDefinition for Health-related quality of life
.... 15.707 OutcomeDefinition for Heart failure
.... 15.708 OutcomeDefinition for Nonfatal myocardial infarction
.... 15.709 OutcomeDefinition for Nonfatal stroke
.... 15.710 OutcomeDefinition for Serious hyperglycaemia
.... 15.711 OutcomeDefinition for Severe gastrointestinal events
.... 15.712 OutcomeDefinition: Injury Severity Score on Impact
.... 15.713 OutcomeDefinition: All-cause mortality
.... 15.714 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.715 OutcomeDefinition: Body weight
.... 15.716 OutcomeDefinition: Cardiovascular mortality
.... 15.717 OutcomeDefinition: Diabetes in remission
.... 15.718 OutcomeDefinition: Diabetic ketoacidosis
.... 15.719 OutcomeDefinition: End-stage kidney disease
.... 15.720 OutcomeDefinition: Genital infection
.... 15.721 OutcomeDefinition: HbA1c at 12 months
.... 15.722 OutcomeDefinition: HbA1c at 24 months
.... 15.723 OutcomeDefinition: HbA1c at 36 months
.... 15.724 OutcomeDefinition: HbA1c at 6 months
.... 15.725 OutcomeDefinition: HbA1c at 60 months
.... 15.726 OutcomeDefinition: Health-related quality of life
.... 15.727 OutcomeDefinition: Heart failure
.... 15.728 OutcomeDefinition: Mortality at 14 days
.... 15.729 OutcomeDefinition: New onset depression
.... 15.730 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.731 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.732 OutcomeDefinition: Nonfatal stroke
.... 15.733 OutcomeDefinition: Serious hyperglycaemia
.... 15.734 OutcomeDefinition: Severe gastrointestinal events
.... 15.735 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.736 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.737 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.738 OutcomeVariable: HbA1c at 12 months
.... 15.739 OutcomeVariable: HbA1c at 24 months
.... 15.740 OutcomeVariable: HbA1c at 36 months
.... 15.741 OutcomeVariable: HbA1c at 6 months
.... 15.742 OutcomeVariable: HbA1c at 60 months
.... 15.743 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.744 OutcomeVariable: New onset depression
.... 15.745 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.746 OutcomeVariable: Remission of diabetes
.... 15.747 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.748 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.749 OutcomeVariable_All_cause_mortality
.... 15.750 OutcomeVariable_Treatment_with_opioids
.... 15.751 Overall survival (NCT05327010)
.... 15.752 PARACHUTE Trial baseline characteristics
.... 15.753 PARACHUTE Trial non participants
.... 15.754 PARACHUTE trial participant flow report
.... 15.755 PARACHUTE Trial Participants
.... 15.756 PARACHUTE Trial Participants assigned an empty backpack
.... 15.757 PARACHUTE trial participants assigned parachute
.... 15.758 PARACHUTE Trial Participants available for randomization
.... 15.759 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.760 PARACHUTE Trial Participants randomized into groups
.... 15.761 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.762 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.763 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.764 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.765 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.766 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.767 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.768 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.769 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.770 PARACHUTE Trial Participants that declined randomization
.... 15.771 PARACHUTE Trial Participants with no contact at 30 days
.... 15.772 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.773 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.774 PARACHUTE Trial Results
.... 15.775 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.776 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.777 Participant Flow Report for NCT03421379
.... 15.778 Participant Flow Report for NCT03640312
.... 15.779 Participant Flow Report for QUARTET USA Trial
.... 15.780 Participant Flow Variables List for PARACHUTE Trial
.... 15.781 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.782 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.783 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.784 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.785 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.786 ParticipantFlowMeasure: Exclusion from analysis
.... 15.787 ParticipantFlowMeasure: Inclusion in analysis
.... 15.788 Participants Excluded from PARACHUTE Study
.... 15.789 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.790 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.791 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.792 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.793 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.794 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.795 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.796 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.797 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.798 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202)
.... 15.799 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.800 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint
.... 15.801 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.802 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.803 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.804 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.805 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.806 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.807 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.808 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.809 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.810 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.811 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.812 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.813 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.814 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.815 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.816 PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk
.... 15.817 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.818 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.819 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.820 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.821 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.822 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.823 Placebo
.... 15.824 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.825 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.826 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.827 Progression-free survival (NCT05327010)
.... 15.828 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.829 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.830 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.831 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.832 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.833 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.834 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.835 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.836 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.837 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.838 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.839 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.840 Quadpill once daily
.... 15.841 QUARTET USA Trial Control Group
.... 15.842 QUARTET USA Trial Quadpill group
.... 15.843 randomized into groups for PARACHUTE Trial
.... 15.844 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.845 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.846 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.847 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.848 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.849 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.850 Reasons for exclusion from QUARTET USA Trial
.... 15.851 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.852 Recommendation Justification Code System
.... 15.853 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.854 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.855 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.856 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.857 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.858 Remdesivir
.... 15.859 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.860 ResearchStudy Classifier Code System
.... 15.861 Results Section for NCT03421379
.... 15.862 Results Section for NCT03640312
.... 15.863 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.864 Risk of Bias Assessment of PARACHUTE trial
.... 15.865 Risk Of Bias Type Value Set
.... 15.866 Screened Group PARACHUTE Trial
.... 15.867 Search Strategy for NMA_Diabetes
.... 15.868 SearchResults: PubMed search for Wonder Woman
.... 15.869 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.870 SearchStrategy: PubMed search for Wonder Woman
.... 15.871 Sex
.... 15.872 Sex with comparator
.... 15.873 Sex with intervention
.... 15.874 SGLT2 inhibitors Group in Adults with diabetes mellitus type 2
.... 15.875 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.876 SMR-excluded Tlayjeh H J Infect Public Health 33008778
.... 15.877 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.878 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.879 Spanish or English Value Set
.... 15.880 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.881 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.882 StudyEligibilityCriteria for M11Report Example
.... 15.883 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.884 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.885 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.886 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.887 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.888 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.889 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.890 Summary of Findings - QUARTET USA Trial
.... 15.891 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.892 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.893 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.894 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.895 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.896 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.897 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.898 Systolic blood pressure at 12 weeks
.... 15.899 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
.... 15.900 Time to integration of results in a recommendation
.... 15.901 Treatment-induced changes in phospho-protein signaling (NCT05327010)
.... 15.902 VariableDefinition: Comparator
.... 15.903 VariableDefinition: Condition(s)
.... 15.904 VariableDefinition: Date of birth
.... 15.905 VariableDefinition: Date of measurement
.... 15.906 VariableDefinition: Gender
.... 15.907 VariableDefinition: NTproBNP
.... 15.908 VariableDefinition: Unit
.... 15.909 Velocity
.... 15.910 Velocity comparing intervention vs. comparator
.... 15.911 Velocity for enrolled group
.... 15.912 Velocity for non participant group
.... 15.913 Velocity with comparator
.... 15.914 Velocity with intervention
.... 15.915 WebPageCitation: A HEvKA Update Summary
.... 15.916 Weight
.... 15.917 Weight with comparator
.... 15.918 Weight with intervention